Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, AMLX, JAZZ, DYN, COGT, and represent 51.13% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: PHVS (+$22M), AMLX (+$18M), DYN (+$15M), ABVX (+$15M), MNPR (+$13M), JAZZ (+$12M), PCVX (+$8.8M), OCUL, XENE, LENZ.
- Started 2 new stock positions in PHVS, MNPR.
- Reduced shares in these 10 stocks: CELC (-$35M), MLTX (-$14M), , ASND (-$6.6M), ARGX (-$5.7M), SNDX, COGT, MRUS, IRON, NAMS.
- Sold out of its positions in ARGX, ASND, CTNM, KALV, MLTX, NBIX, REPL, SLN, SNDX.
- Saturn V Capital Management was a net buyer of stock by $21M.
- Saturn V Capital Management has $456M in assets under management (AUM), dropping by 84.78%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 17 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 14.9 | $68M | +28% | 801k | 84.90 |
|
| Amylyx Pharmaceuticals (AMLX) | 13.7 | $63M | +41% | 4.6M | 13.59 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 8.7 | $40M | +45% | 301k | 131.80 |
|
| Dyne Therapeutics (DYN) | 7.4 | $34M | +83% | 2.7M | 12.65 |
|
| Cogent Biosciences (COGT) | 6.4 | $29M | -11% | 2.0M | 14.36 |
|
| Vaxcyte (PCVX) | 6.2 | $28M | +44% | 788k | 36.02 |
|
| Celcuity (CELC) | 5.1 | $23M | -60% | 474k | 49.40 |
|
| Cg Oncology (CGON) | 5.1 | $23M | 580k | 40.28 |
|
|
| Disc Medicine (IRON) | 4.9 | $23M | -13% | 341k | 66.08 |
|
| Pharvaris N V (PHVS) | 4.8 | $22M | NEW | 886k | 24.95 |
|
| Xenon Pharmaceuticals (XENE) | 4.4 | $20M | +7% | 504k | 40.15 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.9 | $18M | -7% | 735k | 24.25 |
|
| Merus N V (MRUS) | 3.8 | $17M | -17% | 184k | 94.15 |
|
| Lenz Therapeutics (LENZ) | 3.8 | $17M | +7% | 368k | 46.58 |
|
| Ocular Therapeutix (OCUL) | 3.0 | $14M | +58% | 1.2M | 11.69 |
|
| Monopar Therapeutics Com New (MNPR) | 2.8 | $13M | NEW | 155k | 81.67 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.0 | $4.4M | -30% | 153k | 28.44 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2025 Q3 filed Nov. 14, 2025
- Saturn V Capital Management 2025 Q2 filed Aug. 13, 2025
- Saturn V Capital Management 2025 Q1 filed May 15, 2025
- Saturn V Capital Management 2024 Q4 filed Feb. 14, 2025
- Saturn V Capital Management 2024 Q3 filed Nov. 14, 2024
- Saturn V Capital Management 2024 Q2 filed Aug. 14, 2024
- Saturn V Capital Management 2024 Q1 filed May 15, 2024
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023